|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|USRE46375||BDSI||6,7-unsaturated-7-carbamoyl substituted morphinan derivative|| |
(3 years from now)
|USRE46365||BDSI||6,7-unsaturated-7-carbamoyl substituted morphinan derivative|| |
(4 years from now)
|US9108975||BDSI||Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same|| |
(8 years from now)
|US10952968||BDSI||Preparation containing 6,7-unsaturated-7-carbamoyl morphinan derivatives|| |
(9 years from now)
Symproic is owned by Bdsi.
Symproic contains Naldemedine Tosylate.
Symproic has a total of 4 drug patents out of which 0 drug patents have expired.
Symproic was authorised for market use on 23 March, 2017.
Symproic is available in tablet;oral dosage forms.
Symproic can be used as treatment of opioid-induced constipation.
Drug patent challenges can be filed against Symproic from 2021-03-23.
The generics of Symproic are possible to be released after 13 May, 2033.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||Mar 23, 2022|
NCE-1 date: 2021-03-23
Market Authorisation Date: 23 March, 2017
Treatment: Treatment of opioid-induced constipation
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic